|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Johann Wolfgang Goethe University Hospitals |
|---|---|
| Information provided by: | Johann Wolfgang Goethe University Hospitals |
| ClinicalTrials.gov Identifier: | NCT00380926 |
Purpose
Native populations consuming high amounts of fish suffer less from allergic diseases. The purpose of this study is to determine whether polyunsaturated fatty acids (fish oil) might have a disease modifying influence on asthmatics sensitized to house dust mite.
| Condition | Intervention | Phase |
|---|---|---|
|
Allergic Asthma Bronchial Inflammation House Dust Mite Allergy |
Drug: polyunsatturated fatty acids (fish oil) |
Phase II Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Anti-Inflammatory Effect of Polyunsaturated Fatty Acids in Allergic Asthma After Allergen Challenge |
| Estimated Enrollment: | 23 |
| Study Start Date: | April 2004 |
| Estimated Study Completion Date: | November 2004 |
Most asthmatics suffer from mild disease and non pharmacologic intervention would be beneficial for the majority of these subjects. We investigated the anti-inflammatory potential of polyunsaturated fatty acids (PUFA) in allergic asthma.
In our parallel, double-blinded study, 23 patients allergic to house dust mite were randomly assigned to dietary supplementation with a PUFA enriched fat blend or placebo for five weeks. The verum contained eicosapentaenoic acid (EPA) 450 mg/day, docosahexaenoic acid 180 mg/day, stearidonic acid 60mg/day, and gamma-linolenic acid 60 mg/day; the placebo consisted of mainly unsaturated and monosaturated fatty acids. After three weeks, the patients were challenged with low doses of inhalative house dust mite allergen for two weeks.
Following parameters were determined during low-dose allergen exposure in both groups: exhaled NO (eNO) as a marker of bronchial inflammation, clinical symptoms, FEV1, beta-agonist usage, and bronchial hyperreactivity, sputum eosinophils and sulfoleucotrienes. Compliance with the study protocol was controlled by the determination of PUFAs in plasma and erythrocytes.
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | ZAFES-2004-07 |
| Study First Received: | September 25, 2006 |
| Last Updated: | September 28, 2006 |
| ClinicalTrials.gov Identifier: | NCT00380926 History of Changes |
| Health Authority: | Germany: Federal Ministry of Food, Agriculture and Consumer Protection |
|
polyunsatturated fatty acids nutrition low-dose allergen challenge exhaled nitric oxide |
|
Lung Diseases, Obstructive Hypersensitivity Pathologic Processes Respiratory Tract Diseases Bronchial Diseases Immune System Diseases |
Lung Diseases Hypersensitivity, Immediate Asthma Respiratory Hypersensitivity Inflammation |